SOURCE: Radius Health, Inc.
CAMBRIDGE, MA--(Marketwired - Apr 18, 2013) - Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, announced that President and CEO Michael Wyzga will present at the 2013 BIO Business Forum® in Chicago at the 20th BIO International Convention.
The 2013 BIO International Convention is April 22 - 25 at McCormick Place in Chicago, Illinois. Radius' presentation is at 1:30 p.m. (CDT) in the Chicago Bulls Room and will be open to all attendees of the convention.
Mr. Wyzga will provide an update on the company, and BA058, a novel anabolic, bone-building compound under development as a potential treatment for postmenopausal women with osteoporosis at high risk for fracture. BA058-SC, an injectable form of BA058, is currently in a Phase 3 trial, and BA058-TD, is in a Phase 2 trial studying the efficacy of delivering BA058 via transdermal patch. Radius and 3M Drug Delivery Systems have an exclusive partnership agreement for development and commercial supply of BA058-TD.
BIO Business Forum®
April 22, 2013
1:30 p.m. CDT
McCormick Place - Chicago Bulls Room
2301 S. Lake Shore Drive
Chicago, IL 60616
About Radius Health
Radius is a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions. Radius is committed to the development of advanced therapeutics for the large and underserved osteoporosis market. The company's lead product candidate, BA058-SC, is in development to reduce the risk of complications associated with osteoporosis, such as fracture. The company also has a next-generation transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. Learn more by visiting the company's new website at www.RadiusPharm.com